Baylor College of Medicine Selects Illumina, Inc. Infinium(R) High-Density DNA Analysis Products for Molecular Cytogenetic Services

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that researchers at Baylor College of Medicine’s Medical Genetics Laboratories will use Illumina’s Infinium® High-Density (HD) DNA Analysis products to study genomic imprinting and its role in developmental diseases such as Prader-Willi syndrome (PWS), Angelman syndrome (AS), and other disorders caused by uniparental disomy. Baylor College of Medicine is committed to improving human health by providing the most current technologies for the medical genetics community. Illumina is showcasing the latest Information on its High-Density DNA Analysis products for cytogenetic research at the American College of Medical Genetics (ACMG) meeting this week in Tampa, Florida.